SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    AldenkampAP, DodsonWE, eds. Epilepsy and education; cognitive factors in learning behavior. Epilepsia 1990;31(suppl 4):S920.
  • 2
    Dodson WE, Pellock JM. Pediatric epilepsy: diagnosis and treatment. New York : Demos Publications, 1993.
  • 3
    Rapin I. Children with brain dysfunction: neurology, cognition, language and behavior. New York : Raven Press, 1982.
  • 4
    Dodson WE, Trimble MR. Epilepsy and quality of life. New York : Raven Press, 1994.
  • 5
    Aldenkamp AP, Dreifuss FE, Renier WO, Suumeijer PBM. Epilepsy in children and adolescents. Boca Raton, FL: CRC Press, 1995.
  • 6
    Aldenkamp AP. Antiepileptic drug treatment and epileptic seizures–effects on cognitive function. In: TrimbleM, Schmitz B, eds. The neuropsychiatry of epilepsy. New York : Cambridge University Press, 2002: 25667.
  • 7
    Ideström CM, Schalling D, Carlquist U, Sjoqvist F. Acute effects of diphenylhydantoin in relation to plasma levels. Behavioral and psychological studies. Psychol Med 1972;2: 11120.
  • 8
    Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977;27: 10238.
  • 9
    Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995;22: 6595.
  • 10
    Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987;28(suppl 3):3745.
  • 11
    Aldenkamp AP, Alpherts WCJ, Blennow G, et al. Withdrawal of antiepileptic medication—effects on cognitive function in children: The Multicentre Holmfrid Study. Neurology 1993;43: 4150.
  • 12
    Meador KJM, Loring DW, Huh K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsants. Neurology 1990;40: 3914.
  • 13
    American Academy of Pediatrics. Behavioral and cognitive effects of anticonvulsant therapy. Committee on Drugs. Pediatrics 1985;76: 6447.
  • 14
    Loescher W, Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002;50: 316.
  • 15
    Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46: 167883.
  • 16
    Jette NJ, Marson AG, Hutton JL. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(3):CD001417.
  • 17
    Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38: 85980.
  • 18
    Wong IC. New antiepileptic drugs. Study suggests that under a quarter of patients will still be taking the new drugs after six years. Br M J 1997;314: 6034.
  • 19
    Lhatoo SD, Wong ICK, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000;41: 33841.
  • 20
    StefanH, KrämerG, Mamoli, B, eds. Challenge epilepsy—new antiepileptic drugs. Berlin : Blackwell Science, 1998.
  • 21
    Kellet MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66: 75963.
  • 22
    Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000;(2):CD001415.
  • 23
    Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001;46: 25970.
  • 24
    Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996;37(suppl 6):S1722.
  • 25
    Aldenkamp AP. Cognitive and behavioural assessment in clinical trials: when should they be done Epilepsy Res 2001;45: 1559.
  • 26
    Gallassi R, Morreale A, Di Sarro R, Marra M, Lugaresi E, Baruzzi A. Cognitive effects of antiepileptic drug discontinuation. Epilepsia 1992;33(suppl 6):S414.
  • 27
    Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993;44: 52933.
  • 28
    Laaksonen R, Kaimola K, Grahn-Teräväinen E, Waltimo O. A controlled clinical trial of the effects of carbamazepine and oxcarbazepine on memory and attention [Abstract]. 16th International Epilepsy Congress, Hamburg, 1985.
  • 29
    Sabers A, Moller A, Dam M, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995;92: 1927.
  • 30
    Äikiä M, Kälviäinen R, Sivenius J, Halonen T, Riekkinen RJ. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992;11: 199203.
  • 31
    McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994;37: 2732.
  • 32
    White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997;38(suppl 1):S917.
  • 33
    Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46: 168490.
  • 34
    Aldenkamp AP. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 2000;54: 2702.
  • 35
    Aldenkamp AP, Baker G, Mulder OG, et al. A multicentre randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41: 116778.
  • 36
    Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(5 suppl 2):5367.
  • 37
    Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42: 113440.
  • 38
    Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52: 3217.
  • 39
    Meador KJ. Assessing cognitive effects of a new AED without the bias of practice effects [Abstract]. Epilepsia 1997;38(suppl 3):60.
  • 40
    Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997;27: 2932.
  • 41
    Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69: 63641.
  • 42
    Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2: 8591.
  • 43
    Cohen AF, Ashby L, Crowley D, Land G, Peck AW, Miller AA. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985;20: 61929.
  • 44
    Hamilton MJ, Cohen AF, Yuen AW, et al. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 1993;34: 16673.
  • 45
    Meador KJ, Loring DW, Ray PG, Perrine KR, Bazquez BR, Kalbosa T. Differential effects of carbamazepine and lamotrigine [Abstract]. Neurology 2000;54(suppl 3):A84.
  • 46
    Aldenkamp AP, Arends J, Bootsma HP, et al. Randomized, double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002;43: 1926.
  • 47
    Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000;9: 3759.
  • 48
    Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34: 31222.
  • 49
    Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 1991;28: 2307.
  • 50
    Aldenkamp AP, Mulder OG, Overweg J. Cognitive effects of lamotrigine as first line add-on in patients with localized related (partial) epilepsy. J Epilepsy 1997;10: 11721.
  • 51
    Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39: 8747.
  • 52
    Earl N, McKee JR, Sunder TR, et al. Lamotrigine adjunctive therapy in patients with refractory epilepsy and mental retardation [Abstract]. Epilepsia 2000;41(suppl 1):72.
  • 53
    Aarts JH, Binnie CD, Smit AM, Wilkins AJ. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain 1984;107: 293308.
  • 54
    Aldenkamp AP, Arends J, Overweg-Plandsoen TC, et al. Acute cognitive effects of nonconvulsive difficult-to-detect epileptic seizures and epileptiform electroencephalographic discharges. J Child Neurol 2001;16: 11923.
  • 55
    Binnie CD, Emde BW, Kasteleijn-Nolste-Trenite DG, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27: 24854.
  • 56
    Marciani MG, Spanedda F, Bassetti MA, et al. Effect of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis. Br J Clin Pharmacol 1996;42: 6217.
  • 57
    Marciani MG, Stanzione P, Mattia D, et al. Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol 1998;21: 417.
  • 58
    Mervaala E, Koivista K, Hanninen T, et al. Electrophysiological and neuropsychological profiles of lamotrigine in young and age-associated memory impairment (AAMI) subjects [Abstract]. Neurology 1995;45(suppl 4):A259.
  • 59
    Neyens LGJ, Alpherts WCJ, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995;19: 4119.
  • 60
    Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48: 102531.
  • 61
    Kälviäinen R, Äikiä M, Mervaala E, Saukkonen AM, Pitkanen A, Riekkinen PJ Sr. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996;25: 2917.
  • 62
    Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3: 2935.
  • 63
    Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999;40: 127985.
  • 64
    Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997;62: 3726.
  • 65
    Mortimore C, Trimble M, Emmers E. Effects of gabapentin on cognition and quality of life in patients with epilepsy. Seizure 1998;7: 35964.